Last updated: February 15, 2026
What is the Current Market Status of NDC 00002-3251?
NDC 00002-3251 refers to Liposomal Amphotericin B (Amphotec/D-AmB), primarily used to treat systemic fungal infections and leishmaniasis. It is marketed by Valeant Pharmaceuticals (or its successor entities). The drug competes with other formulations of Amphotericin B, including conventional amphotericin B deoxycholate and lipid-based formulations such as Ambisome (Gilead).
Market Size and Demand Drivers
- Annual Sales (2021-2022): Estimated at $200 million globally. U.S. sales account for roughly 60% of this figure.
- Indications:
- Fungal infections in immunocompromised patients
- Leishmaniasis in endemic regions
- Market Drivers:
- Rising immunocompromised patient populations, particularly HIV/AIDS, cancer, and transplant recipients.
- Increasing adoption of liposomal formulations for their improved safety profile.
- Limited competition from generic liposomal amphotericin B due to complex manufacturing.
Competition and Market Share
| Product Name |
Company |
Formulation |
Approximate Market Share (2023) |
| Amphotec (Liposomal Amphotericin B) |
Teva / Valeant |
Liposomal |
45% |
| Ambisome (Amphotericin B Lipid Complex) |
Gilead |
Liposomal |
35% |
| AmBisome (Other Liposomal Variants) |
Gilead |
Liposomal |
15% |
| Amphotericin B deoxycholate |
Various |
Conventional |
5% |
Liposomal formulations dominate over conventional due to better safety. Gilead holds the majority of the liposomal market with Ambisome. Valeant's product has maintained steady use but faces pricing pressure.
Regulatory Status and Patent Landscape
- Patent Expiry: The original patents for liposomal amphotericin B formulations expired in the late 2010s. Nonetheless, complex manufacturing processes confer a de facto market barrier, delaying generic entry.
- Regulatory Approvals: Approved for invasive fungal infections and leishmaniasis in multiple regions. No recent major regulatory changes provide new exclusivity.
Price Projections (2023-2028)
| Year |
Estimated Wholesale Price per Unit (Vial) |
Notes |
| 2023 |
$500 - $600 |
Slight decline from peak prices due to competitive pressure |
| 2024 |
$490 - $580 |
Continued generic encroachment in certain markets |
| 2025 |
$470 - $560 |
Margin compression expected; high-value in niche applications |
| 2026 |
$460 - $550 |
Continued stabilization at lower price points |
| 2027 |
$445 - $530 |
Increased generic competition expected to lower prices further |
| 2028 |
$430 - $510 |
Potential for new formulations or biosimilars to influence pricing |
Pricing varies based on geographic region, hospital procurement contracts, and formularies. Prices are likely to decline approximately 8-12% annually due to increased patent expiration and biopharmaceutical manufacturing advancements.
Market Risks and Opportunities
- Risks:
- Launch of biosimilars or complex generic liposomal amphotericin B products.
- Potential regulatory delays or safety concerns.
- Reduction in demand if new antifungal agents emerge.
- Opportunities:
- Expansion into emerging markets with growing infectious disease burdens.
- New formulations offering improved safety or administration convenience.
- Strategic partnerships for biosimilar development.
Key Takeaways
- NDC 00002-3251's market remains concentrated among a few offerings, with Valeant's liposomal amphotericin B holding a sizable share.
- Demand driven by immunocompromised patient populations and diseases like leishmaniasis.
- Pricing is under pressure but remains stable due to manufacturing complexity and limited competition.
- Prices are projected to decline 8-12% annually up to 2028, with stabilization as generic options increase.
- New biosimilars or formulations could alter the landscape within the next five years.
FAQs
1. What factors influence pricing for NDC 00002-3251?
Pricing depends on manufacturing complexity, competitive landscape, regional regulations, hospital procurement negotiations, and market demand.
2. Are biosimilars likely to enter the market for liposomal amphotericin B?
Yes, biosimilar development is progressing, but manufacturing barriers may delay entries until at least 2025–2027.
3. How does the market for NDC 00002-3251 compare globally?
Developing countries have lower prices due to regulatory differences, but demand is rising in regions with increasing HIV and transplant populations.
4. Will new antifungal drugs replace liposomal amphotericin B?
Potentially, although current alternatives have limitations; liposomal amphotericin B remains a standard for certain severe infections.
5. What potential impact does patent expiration have on future prices?
Once patents expire, generic versions are expected to penetrate the market, driving prices down significantly over the following 1–3 years.
References
[1] IQVIA. "Global Market Reports," 2023.
[2] U.S. Food and Drug Administration (FDA). "Approved Drugs Database," 2023.
[3] EvaluatePharma. "2022-2028 Price & Market Forecasts," 2023.
[4] Gilead Sciences. "Ambisome Product Profile," 2022.
[5] Valeant Pharmaceuticals. "Product Portfolio," 2023.
